Table 1.
Characteristics of non-alcoholic fatty liver disease patients (n = 49).
| Characteristics | Total |
|---|---|
| Age, y | 58 (11.28) |
| Men, n (%) | 40 (81.63) |
| Waist circumference, cm | 105 (14.01) |
| Body mass index, kg/m2 | 30.1 (5.5) |
| Overweight, n (%) | 21 (42.86) |
| Obesity, n (%) | |
| Class 1 | 14 (28.57) |
| Class 2 | 4 (8.16) |
| Class 3 | 3 (6.12) |
| Total body fat (CUNBAE), % | 33.79 (8.15) |
| VAT, mL | 4558.57 (2113.57) |
| SCAT, mL | 6905.98 (3873.47) |
| VAT/SCAT ratio | 0.74 (0.41) |
| Hypertension, n (%) | 19 (38.78) |
| Impaired fasting glucose, n (%) | 18 (36.73) |
| Diabetes, n (%) | 11 (22.45) |
| Dyslipidaemia, n (%) | 24 (48.98) |
| OSA, n (%) | 7 (14.30) |
| Smoking, n (%) | |
| Current | 10 (20.41) |
| Former | 22 (44.90) |
| Never | 17 (34.69) |
| CVD family history, n (%) | 10 (20.41) |
| Antihypertensive therapy, n (%) | 16 (32.70) |
| Glucose lowering therapy, n (%) | 8 (16.30) |
| Metformin | 5 (10.20) |
| Glinides | 1 (2.00) |
| SGLT2 inhibitors | 3 (6.10) |
| DPP4 inhibitors | 3 (6.10) |
| Statin therapy, n (%) | 13 (26.50) |
| Aspirin therapy, n (%) | 3 (6.10) |
| Hypouricemic therapy, n (%) | 4 (8.20) |
| Glucose, mg/dL | 111 (30) |
| HbA1c, % | 6.0 (1.0) |
| Insulin, U/mL | 16.24 (8.86) |
| HOMA-IR | 1.36 (2.50) |
| Triacylglycerol, mg/dL | 127 (55) |
| Total cholesterol, mg/dL | 188 (44) |
| LDL cholesterol, mg/dL | 120 (57) |
| HDL cholesterol, mg/dL | 50 (15) |
| ALT, IU/L | 36 (23.40) |
| AST, IU/L | 23 (11.57) |
| AST/ALT | 0.7 (0.25) |
| ALP, IU/L, median (p25, p75) | 47 (28, 74) |
| GGT, IU/L | 64 (33.66) |
| Platelet count, × 103/µL | 228 (62.97) |
| Albumin, g/dL | 4.78 (0.32) |
| Urate, mg/dL | 11.2 (15.3) |
| Creatinine, mg/dL | 3.9 (13.8) |
| Urine albumin to creatinine ratio, mg/g | 4.9 (2.2) |
Values are expressed as mean (SD), unless otherwise stated.
ALT Alanine transaminase, ALP alkaline phosphatase, AST aspartate transaminase, BMI body mass index, CUNBAE Clínica Universidad de Navarra-Body Adiposity Estimator, CVD cardiovascular disease. DPP4 dipeptidyl peptidase 4, GGT gamma-glutamyl transpeptidase, HbA1c hemoglobin A1c, HOMA-IR homeostatic model assessment of insulin resistance, OSA obstructive sleep apnea, SCAT subcutaneous adipose tissue, SGLT2 sodium-glucose co-transporter-2, VAT visceral adipose tissue.